Whitespace Analysis

Find crowded markets, emerging opportunities, and underserved indications by trial activity and sponsor concentration.

Limited-time launch pricing

$99/month

30-day free trial - no credit card

Upgrade to Pro

Or explore free dashboards — PDUFA calendar, Trials Explorer, Biotechs, and more.

Competitive Density Analysis

Data updated: Jul 17, 2026

Trial activity, Phase 3 concentration, and competitive dynamics by indication

Current Metrics: Based on ClinicalTrials.gov data (active trials, phases, sponsors).

Future Enhancement: True "white space" analysis (trials vs approved drugs) requires mapping FDA-approved drugs to our indication taxonomy. FDA labels use specific terms like "HER2+ metastatic breast carcinoma" while our taxonomy uses broader categories like "Breast Cancer". This mapping is in progress.

Highest Trial Activity

Most active indications by total trial count

Indication	TA	Active Trials	Phase 3	Phase 2	Sponsors
Solid Tumor (Advanced)	Oncology	3553	387	1786	779
Non-Hodgkin Lymphoma	Oncology	1640	180	1036	229
Breast Cancer	Oncology	1529	330	897	196
NSCLC	Oncology	1478	284	883	329
Colorectal Cancer	Oncology	1158	191	728	232
Prostate Cancer	Oncology	884	162	524	152
AML	Oncology	699	81	369	114
Multiple Myeloma	Oncology	681	113	394	91
Pancreatic Cancer	Oncology	667	74	409	194
Hepatocellular Carcinoma	Oncology	632	94	379	121
Hematologic Malignancies	Oncology	565	60	326	84
Lung Cancer (General)	Oncology	563	77	341	102
Ovarian Cancer	Oncology	553	84	297	166
Head and Neck Cancer	Oncology	536	55	338	153
Obesity	Metabolic	524	137	172	93

Late-Stage Concentration

Highest Phase 3 activity (near-term competitive pressure)

Indication	TA	Phase 3	% of Trials	Active	Sponsors
Solid Tumor (Advanced)	Oncology	387	11%	3553	779
Breast Cancer	Oncology	330	22%	1529	196
NSCLC	Oncology	284	19%	1478	329
Colorectal Cancer	Oncology	191	16%	1158	232
Non-Hodgkin Lymphoma	Oncology	180	11%	1640	229
Prostate Cancer	Oncology	162	18%	884	152
Stroke	Cardiovascular	159	43%	373	54
Obesity	Metabolic	137	26%	524	93
Multiple Myeloma	Oncology	113	17%	681	91
Acute Pain	Pain	98	25%	400	42
Hypertension	Cardiovascular	96	29%	332	93
Hepatocellular Carcinoma	Oncology	94	15%	632	121

Concentrated Markets

Few sponsors running many trials (potential dominance or acquisition targets)

Indication	TA	Trials/Sponsor	Active	Sponsors
H. pylori	Infectious Disease	19	57	3
HIV	Infectious Disease	17.6	317	18
Chronic Pain	Pain	16.3	65	4
Opioid Use Disorder	CNS	14.6	131	9
Postoperative Pain	Pain	14.5	188	13
Sepsis	Infectious Disease	14.1	113	8
Atrial Fibrillation	Cardiovascular	12.5	125	10
Alcohol Use Disorder	CNS	12.4	112	9
Nausea/Vomiting	Gastrointestinal	12	48	4
PTSD	CNS	11.7	82	7

Fragmented Markets

Many sponsors competing (crowded, potentially commoditized)

Indication	TA	Sponsors	Active	Phase 3
Solid Tumor (Advanced)	Oncology	779	3553	387
NSCLC	Oncology	329	1478	284
Colorectal Cancer	Oncology	232	1158	191
Non-Hodgkin Lymphoma	Oncology	229	1640	180
Breast Cancer	Oncology	196	1529	330
Pancreatic Cancer	Oncology	194	667	74
Ovarian Cancer	Oncology	166	553	84
Head and Neck Cancer	Oncology	153	536	55
Prostate Cancer	Oncology	152	884	162
Melanoma	Oncology	142	521	61

Showing top indications in each category

Upgrade to Pro for full competitive density analysis across 150 indications

See Pro Features

Methodology

Data Source: ClinicalTrials.gov (Phase 2-4 interventional drug trials, 2008+)

Active Trials: Status = Recruiting, Active, or Enrolling by Invitation

Trials/Sponsor: Average trials per company in that indication. Higher = concentrated market.

Phase 3 %: Proportion of active trials in Phase 3. Higher = more near-term competitive pressure.